RU2141966C1 - Антиандрогенные соединения, предшественник антиандрогенного соединения, фармацевтические композиции - Google Patents

Антиандрогенные соединения, предшественник антиандрогенного соединения, фармацевтические композиции Download PDF

Info

Publication number
RU2141966C1
RU2141966C1 RU94046463A RU94046463A RU2141966C1 RU 2141966 C1 RU2141966 C1 RU 2141966C1 RU 94046463 A RU94046463 A RU 94046463A RU 94046463 A RU94046463 A RU 94046463A RU 2141966 C1 RU2141966 C1 RU 2141966C1
Authority
RU
Russia
Prior art keywords
mixture
mmol
antiandrogenic
hydroxy
androsten
Prior art date
Application number
RU94046463A
Other languages
English (en)
Russian (ru)
Other versions
RU94046463A (ru
Inventor
Лабри Фернанд
Меранд Ив
М.Сингх Шанкар
Original Assignee
Андорешерш Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Андорешерш Инк. filed Critical Андорешерш Инк.
Publication of RU94046463A publication Critical patent/RU94046463A/ru
Application granted granted Critical
Publication of RU2141966C1 publication Critical patent/RU2141966C1/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
    • C07J1/0037—Androstane derivatives substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being a saturated hydrocarbon group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
    • C07J1/004—Androstane derivatives substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0044—Alkenyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
    • C07J1/004—Androstane derivatives substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0048—Alkynyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/006—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton spiro-condensed

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
RU94046463A 1993-05-17 1993-05-20 Антиандрогенные соединения, предшественник антиандрогенного соединения, фармацевтические композиции RU2141966C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6061293A 1993-05-17 1993-05-17
US08/060,612 1993-05-17
PCT/CA1993/000216 WO1994026767A1 (en) 1993-05-17 1993-05-20 Improved antiandrogens

Publications (2)

Publication Number Publication Date
RU94046463A RU94046463A (ru) 1997-02-27
RU2141966C1 true RU2141966C1 (ru) 1999-11-27

Family

ID=22030624

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94046463A RU2141966C1 (ru) 1993-05-17 1993-05-20 Антиандрогенные соединения, предшественник антиандрогенного соединения, фармацевтические композиции

Country Status (14)

Country Link
EP (1) EP0650495B1 (OSRAM)
JP (1) JP2741286B2 (OSRAM)
KR (1) KR100241228B1 (OSRAM)
AT (1) ATE197458T1 (OSRAM)
CA (1) CA2136303A1 (OSRAM)
CZ (2) CZ285893B6 (OSRAM)
DE (1) DE69329649D1 (OSRAM)
FI (1) FI945458L (OSRAM)
HU (1) HUT69408A (OSRAM)
PL (1) PL307333A1 (OSRAM)
RU (1) RU2141966C1 (OSRAM)
SK (1) SK139194A3 (OSRAM)
TW (1) TW259791B (OSRAM)
WO (1) WO1994026767A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5879711A (en) * 1997-11-07 1999-03-09 Sequeira; Joel A. Stable antiandrogenic gel composition
BR9908592A (pt) 1998-03-11 2001-04-24 Endorech Inc Processo para inibir a atividade de 17ß-hidroxiesteróide desidrogenase tipo 5, composição farmacêutica, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 5, processo para inibir 17ß-hidroxiesteróide desidrogenase tipo 3, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 3, processos para tratar, ou reduzir o risco de desenvolver, câncer da próstata, hiperplasia prostática benigna, acne, seborréia, hirsutismo ou alopécia androgênica, sìndrome de ovário policìstico, câncer de mama, endometriose ou leiomioma, para inibir as secreções hormonais testiculares, para tratar puberdade precoce, e, kit
WO2002089802A2 (en) 2001-05-08 2002-11-14 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
KR100991616B1 (ko) 2001-09-06 2010-11-04 쉐링 코포레이션 안드로겐 의존성 질환 치료용 17β-하이드록시스테로이드데하이드로게나제 유형 3 억제제
PE20030705A1 (es) 2001-10-17 2003-08-21 Schering Corp Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes
AU2003219656B2 (en) * 2002-01-15 2007-05-17 Merck Sharp & Dohme Corp. 17-hydroxy-4-aza-androstan-3-ones as androgen receptor modulators
US7074795B2 (en) 2002-11-18 2006-07-11 Schering Corporation 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
CA2509758A1 (en) 2002-12-17 2004-07-22 Schering Corporation 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
GB0722779D0 (en) 2007-11-20 2008-01-02 Sterix Ltd Compound

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1081494A (en) * 1965-09-14 1967-08-31 British Drug Houses Ltd 17ª‡-(alka-1',3'-diynyl)-steroids

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3875188A (en) * 1968-04-10 1975-04-01 Eugene E Galantay 17-Beta-alpha-lower alkyl allene-substituted steroids
JPS5513273A (en) * 1978-07-13 1980-01-30 Kanebo Ltd Readily absorbable thiazolidine prodrug of anti- inflammatory corticosteroid and its drug composition
FR2430952A1 (fr) * 1978-07-13 1980-02-08 Roussel Uclaf Nouveaux derives acetyleniques de l'androst 4-ene, leur procede de preparation et leur application comme medicament
WO1991000732A1 (en) * 1989-07-07 1991-01-24 Endorecherche Inc. Androgen derivatives for use in the inhibition of sex steroid activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1081494A (en) * 1965-09-14 1967-08-31 British Drug Houses Ltd 17ª‡-(alka-1',3'-diynyl)-steroids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Машковский М.Д. Лекарственные средства. - М.: Медицина, 1993, т. 2, с. 550 - 552. *

Also Published As

Publication number Publication date
DE69329649D1 (de) 2000-12-14
HUT69408A (en) 1995-09-28
ATE197458T1 (de) 2000-11-11
EP0650495B1 (en) 2000-11-08
JP2741286B2 (ja) 1998-04-15
CA2136303A1 (en) 1994-11-24
SK139194A3 (en) 1995-07-11
WO1994026767A1 (en) 1994-11-24
CZ282494A3 (en) 1995-12-13
CZ285893B6 (cs) 1999-11-17
RU94046463A (ru) 1997-02-27
EP0650495A1 (en) 1995-05-03
KR100241228B1 (ko) 2000-02-01
JPH08510988A (ja) 1996-11-19
PL307333A1 (en) 1995-05-15
FI945458A0 (fi) 1994-11-21
FI945458A7 (fi) 1995-01-16
TW259791B (OSRAM) 1995-10-11
FI945458L (fi) 1995-01-16
CZ287991B6 (cs) 2001-03-14

Similar Documents

Publication Publication Date Title
RU2141967C1 (ru) ИНГИБИТОРЫ ТЕСТОСТЕРОН 5α-РЕДУКТАЗЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ИНГИБИРОВАНИЯ АКТИВНОСТИ ТЕСТОСТЕРОН 5α-РЕДУКТАЗЫ
EP0133995B1 (en) Steroids and therapeutic compositions containing same
JP4845320B2 (ja) （７α，１１β）−ジメチル−１７β−ヒドロキシ−４−エストレン−３−オンの４−Ｎ−ブチルシクロヘキサン酸エステル及びウンデカン酸エステルの製造方法及びそれらの医学用途
KR100270432B1 (ko) 성스테로이드활성억제용에스트로겐핵유도체
RU2141966C1 (ru) Антиандрогенные соединения, предшественник антиандрогенного соединения, фармацевтические композиции
JPH0383996A (ja) Ｃ１７‐２０リアーゼ阻害剤として有用な４‐置換１７β‐（シクロプロピロキシ）アンドロスト‐５‐エン‐３β‐オール及び関連化合物類
FR2485544A1 (fr) (propadiene-1,2 yl)-10 steroides inhibiteurs irreversibles des aromatases, utiles notamment comme medicaments inhibiteurs de la production d'oestrogenes, compositions therapeutiques et formes pharmaceutiques les contenant et intermediaires pour la preparation de ces steroides
US6015806A (en) Antiandrogens
JP2750621B2 (ja) ３β，１７β―ヒドロキシ―置換ステロイド及び関連するステロイド化合物類
NO168892B (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 17beta-(cyclopropyloxy)androst-5-en-3beta-ol-derivater
JPH04290898A (ja) アローマターゼ抑制剤としての２β，１９−エチレン架橋ステロイド類
WO2002000681A1 (en) 20-fluoro-17(20)-vinyl steroids as inhibitors of c17-20-lyase and 5-alpha reductase
US20020019548A1 (en) 20-Fluoro-17(20)-vinyl steroids
JP3537769B2 (ja) エキレニン誘導体、その製造法および該化合物を含有する医薬品
AU718358B2 (en) Inhibitors of testosterone 5-alpha reductase activity
Johnson Endocrine aspects and hormonal treatment of hepatocellular carcinoma: An overview
Bhatnagar et al. Experimental comparative studies with the new aromatase inhibitors CGS 16949 and CGS 20267
IE73240B1 (en) Steroids and therapeutic compositions containing same
NZ280175A (en) Inhibiting testosterone 5alpha-reductase activity using an A ring modified 4-aza-3-oxo-cyclopentanoperhydrophenarthrene substituted in position-17beta by amino or acylamino